<DOC>
	<DOCNO>NCT00488163</DOCNO>
	<brief_summary>Relationships alter prefrontal cortical dopamine , norepinephrine cognitive impairment schizophrenia support approach pharmacological remediation cognitive symptom manipulation prefrontal cortical dopamine norepinephrine . Atomoxetine , selective norepinephrine re-uptake inhibitor , produce widespread increase brain norepinephrine secondary selective increase prefrontal dopamine . Given , evaluate atomoxetine ’ cognitive effect pilot placebo control trial patient schizophrenia . Moreover , fMRI investigation undertaken assess neural mechanism underlie cognitive effect atomoxetine .</brief_summary>
	<brief_title>Pilot Study Atomoxetine To Enhance COgnition In Patients With Schizophrenia</brief_title>
	<detailed_description>Participants carry diagnosis schizophrenia receive treatment one follow antipsychotic medication eleigible participation : risperidone , olanzapine , quetiapine , aripirazole . Following consent , participant observe 4 week ensure stability symptom . Following , baseline assessment symptom severity , cognitive ability , functional ability fMRI scan . Following , participant randomly assign receive treatment 40 mg atomoxetine placebo daily double-blind parallel design four week treatment period , follow dose atomoxetine increase 40 mg twice day ( match placebo ) additional 4 week . The cognitive assessment battery MRI repeat follow 8 week treatment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1 . Subjects males female age 18 65 2 . In good general medical health 3 . For patient subject , DSMIV diagnosis schizophrenia , subtype 4 . Currently remission stable , unchanging residual symptom 5 . Receiving treatment olanzapine , aripiprazole , risperidone , quetiapine antipsychotic medication stable dose minimum eight week . 6 . Able complete neurocognitive test 7 . Able give inform consent . All subject require least 8th grade read level and/or fullscale IQ least 85 assessed Wide Range Achievement Test ( WRAT ) . 1 . Recent history ( within previous year ) serious suicide , homicide , physical violence , current suicidal homicidal thought 2 . Any axis I DSMIV diagnosis addition schizophrenia schizoaffective disorder except substance abuse remission 3 . History severe head trauma , neurological disorder , medical illness may contribute subject ’ psychiatric symptom cognitive impairment 4 . Medical illness require take medication CNS activity know impair cognition . 5 . Untreated unstable hypertension . 6 . Coronary artery disease . 7 . Receiving concomitant anticholinergic drug , antidepressant mood stabilizer . If patient subject receive benzodiazepine , must short intermediate acting ( e.g . alprazolam , lorazepam ) must hold 48 hour prior cognitive test 8 . Unable give inform consent 9 . History developmental disorder less eighth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>cognition</keyword>
	<keyword>atomoxetine</keyword>
	<keyword>norepinephrine</keyword>
	<keyword>dopamine</keyword>
</DOC>